{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:36:49Z","timestamp":1765888609707,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Proper monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with antiemetics is crucial for cancer patients. This study aimed to evaluate the use of antiemetics for the treatment of highly emetogenic chemotherapy (HEC) including carboplatin in the real-world setting in Spain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A representative panel of cancer specialists was asked to collect information about the antiemetic treatments provided to patients receiving chemotherapy. Records formed part of the Global Oncology Monitor<jats:sup>\u00a9<\/jats:sup> database (Ipsos Healthcare, London, UK). Chemotherapy data were extrapolated using Ipsos Healthcare\u2019s projection methodology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 73 experts were finally included. Data from 9519 patients, estimated to be representative of 202,084 patients, were collected. HEC (and carboplatin-based chemotherapy) was administered to 73,118 (36%) patients, cisplatin-based therapy being the most frequent treatment (<jats:italic>n<\/jats:italic>\u2009=\u200934,649, 47.38%). Neurokinin-1 receptor antagonists (NK<jats:sub>1<\/jats:sub>RAs) alone or in combination were used as prophylaxis for CINV in 14,762 (20%) patients, while the combination of NK<jats:sub>1<\/jats:sub>RA with 5-hydroxytryptamine-3 receptor antagonist (5-HT<jats:sub>3<\/jats:sub>RAs) and dexamethasone as recommended by the international guidelines was used in 5849 (8%) patients only. No antiemetic prophylaxis was administered to 8.46% of the patients receiving HEC (<jats:italic>n<\/jats:italic>\u2009=\u20096189). Physicians classified cisplatin-, anthracycline-cyclophosphamide (AC-), and carboplatin-based regimens as HEC in 63%, 22% and 4% of the cases, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The use of NK<jats:sub>1<\/jats:sub>RA-containing regimens for CINV prevention in patients treated with HEC was less than expected, suggesting poor adherence to international antiemetic guidelines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-021-02623-8","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T09:03:13Z","timestamp":1620291793000},"page":"2155-2162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5492-6739","authenticated-orcid":false,"given":"Y.","family":"Escobar \u00c1lvarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"De Castro Carpe\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Drago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Franceschetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"issue":"1","key":"2623_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","volume":"142","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat. 2013;142(1):101\u20137. https:\/\/doi.org\/10.1007\/s10549-013-2727-3.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2623_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13(4):219\u201327. https:\/\/doi.org\/10.1007\/s00520-004-0710-6.","journal-title":"Support Care Cancer"},{"issue":"12","key":"2623_CR3","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","volume":"20","author":"P Fernandez-Ortega","year":"2012","unstructured":"Fernandez-Ortega P, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients\u2019 quality of life. Support Care Cancer. 2012;20(12):3141\u20138. https:\/\/doi.org\/10.1007\/s00520-012-1448-1.","journal-title":"Support Care Cancer"},{"issue":"14","key":"2623_CR4","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374(14):1356\u201367. https:\/\/doi.org\/10.1056\/NEJMra1515442.","journal-title":"N Engl J Med"},{"issue":"6","key":"2623_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jpainsymman.2015.12.317","volume":"51","author":"A Molassiotis","year":"2016","unstructured":"Molassiotis A, et al. Anticipatory nausea, risk factors, and its Impact on chemotherapy-induced nausea and vomiting: results from the Pan European Emesis Registry study. J Pain Symptom Manag. 2016;51(6):987\u201393. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.12.317.","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"2623_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch E, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197\u20138. https:\/\/doi.org\/10.1001\/jama.2017.7156.","journal-title":"JAMA"},{"issue":"6","key":"2623_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/jco.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557\u201365. https:\/\/doi.org\/10.1200\/jco.2015.63.0830.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2623_CR8","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23(8):1986\u201392. https:\/\/doi.org\/10.1093\/annonc\/mds021.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"2623_CR9","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","volume":"19","author":"SM Grunberg","year":"2011","unstructured":"Grunberg SM, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2013state of the art. Support Care Cancer. 2011;19(Suppl 1):S43\u20137. https:\/\/doi.org\/10.1007\/s00520-010-1003-x.","journal-title":"Support Care Cancer"},{"issue":"1","key":"2623_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/jco.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103\u20139. https:\/\/doi.org\/10.1200\/jco.1997.15.1.103.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2623_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00520-016-3449-y","volume":"25","author":"LH Einhorn","year":"2017","unstructured":"Einhorn LH, et al. 2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017;25(1):303\u20138. https:\/\/doi.org\/10.1007\/s00520-016-3449-y.","journal-title":"Support Care Cancer"},{"issue":"suppl 5","key":"2623_CR12","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdw270.","journal-title":"Ann Oncol"},{"doi-asserted-by":"publisher","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines (NCCN Guidelines\u00ae). Antiemesis. 2020. Version 1.2020, 2020. Accessed [April 2020]; https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/17512433.2019.1621162","key":"2623_CR13","DOI":"10.1080\/17512433.2019.1621162"},{"issue":"24","key":"2623_CR14","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782\u201397. https:\/\/doi.org\/10.1200\/JCO.20.01296.","journal-title":"J Clin Oncol"},{"issue":"28","key":"2623_CR15","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/jco.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(28):3240\u201361. https:\/\/doi.org\/10.1200\/jco.2017.74.4789.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2623_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/17512433.2019.1621162","volume":"12","author":"M Karthaus","year":"2019","unstructured":"Karthaus M, et al. Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults. Expert Rev Clin Pharmacol. 2019;12(7):661\u201380. https:\/\/doi.org\/10.1080\/17512433.2019.1621162.","journal-title":"Expert Rev Clin Pharmacol"},{"unstructured":"MASCC\/ESMO. 2019 updated MASCC\/ESMO Antiemetic Guidelines. Accessed [April 2020]; https:\/\/www.mascc.org\/antiemetic-guideline-publications","key":"2623_CR17"},{"issue":"1","key":"2623_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","volume":"19","author":"TA Burke","year":"2011","unstructured":"Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. 2011;19(1):131\u201340. https:\/\/doi.org\/10.1007\/s00520-009-0797-x.","journal-title":"Support Care Cancer"},{"issue":"6","key":"2623_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00520-010-0915-9","volume":"19","author":"A Haiderali","year":"2011","unstructured":"Haiderali A, et al. Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support Care Cancer. 2011;19(6):843\u201351. https:\/\/doi.org\/10.1007\/s00520-010-0915-9.","journal-title":"Support Care Cancer"},{"issue":"5","key":"2623_CR20","first-page":"273","volume":"8","author":"L Schwartzberg","year":"2015","unstructured":"Schwartzberg L, et al. Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens. Am Health Drug Benefits. 2015;8(5):273\u201382.","journal-title":"Am Health Drug Benefits"},{"key":"2623_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","volume":"99","author":"S Sommariva","year":"2016","unstructured":"Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol. 2016;99:13\u201336. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.12.001.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2623_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/cncr.22823","volume":"110","author":"YC Tina Shih","year":"2007","unstructured":"Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110(3):678\u201385. https:\/\/doi.org\/10.1002\/cncr.22823.","journal-title":"Cancer"},{"issue":"1","key":"2623_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/annonc\/mdj078","volume":"17","author":"F Roila","year":"2006","unstructured":"Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006;17(1):20\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdj078.","journal-title":"Ann Oncol"},{"issue":"3","key":"2623_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1078155214524809","volume":"21","author":"F Caracuel","year":"2015","unstructured":"Caracuel F, et al. Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital. J Oncol Pharm Pract. 2015;21(3):163\u20139. https:\/\/doi.org\/10.1177\/1078155214524809.","journal-title":"J Oncol Pharm Pract"},{"key":"2623_CR25","first-page":"144","volume":"9","author":"J S\u00e1ez-De la Fuente","year":"2007","unstructured":"S\u00e1ez-De la Fuente J, et al. Variabilidad de las pautas antiem\u00e9ticas en un hospital oncol\u00f3gico. Atenci\u00f3n Farmac\u00e9utica. 2007;9:144\u201353.","journal-title":"Atenci\u00f3n Farmac\u00e9utica"},{"issue":"1","key":"2623_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00520-010-1079-3","volume":"20","author":"H Burmeister","year":"2012","unstructured":"Burmeister H, et al. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2012;20(1):141\u20137. https:\/\/doi.org\/10.1007\/s00520-010-1079-3.","journal-title":"Support Care Cancer"},{"issue":"1","key":"2623_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/jop.2012.000816","volume":"10","author":"JW Gilmore","year":"2014","unstructured":"Gilmore JW, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract. 2014;10(1):68\u201374. https:\/\/doi.org\/10.1200\/jop.2012.000816.","journal-title":"J Oncol Pract"},{"issue":"5","key":"2623_CR28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1365-2354.2007.00872.x","volume":"17","author":"A Molassiotis","year":"2008","unstructured":"Molassiotis A, et al. Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care (Engl). 2008;17(5):444\u201353. https:\/\/doi.org\/10.1111\/j.1365-2354.2007.00872.x.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"4","key":"2623_CR29","doi-asserted-by":"publisher","first-page":"e1127","DOI":"10.1002\/cnr2.1127","volume":"1","author":"M Aapro","year":"2018","unstructured":"Aapro M, et al. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep. 2018;1(4):e1127. https:\/\/doi.org\/10.1002\/cnr2.1127.","journal-title":"Cancer Rep"},{"issue":"2","key":"2623_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00520-017-3866-6","volume":"26","author":"R Clark-Snow","year":"2018","unstructured":"Clark-Snow R, Affronti ML, Rittenberg CN. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer. 2018;26(2):557\u201364. https:\/\/doi.org\/10.1007\/s00520-017-3866-6.","journal-title":"Support Care Cancer"},{"issue":"11","key":"2623_CR31","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1007\/s00520-019-04697-1","volume":"27","author":"P Dielenseger","year":"2019","unstructured":"Dielenseger P, et al. Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey. Support Care Cancer. 2019;27(11):4099\u2013106. https:\/\/doi.org\/10.1007\/s00520-019-04697-1.","journal-title":"Support Care Cancer"},{"issue":"12","key":"2623_CR32","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s00520-010-1042-3","volume":"19","author":"M Majem","year":"2011","unstructured":"Majem M, et al. Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer. 2011;19(12):1983\u201390. https:\/\/doi.org\/10.1007\/s00520-010-1042-3.","journal-title":"Support Care Cancer"},{"issue":"1","key":"2623_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00520-018-4323-x","volume":"27","author":"DS Childs","year":"2019","unstructured":"Childs DS, et al. What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study. Support Care Cancer. 2019;27(1):249\u201355. https:\/\/doi.org\/10.1007\/s00520-018-4323-x.","journal-title":"Support Care Cancer"},{"issue":"8","key":"2623_CR34","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/jco.2014.57.9334","volume":"33","author":"M Di Maio","year":"2015","unstructured":"Di Maio M, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015;33(8):910\u20135. https:\/\/doi.org\/10.1200\/jco.2014.57.9334.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2623_CR35","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s00520-015-2750-5","volume":"23","author":"C Vidall","year":"2015","unstructured":"Vidall C, et al. Impact and management of chemotherapy\/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists\/oncology nurses and patients: a cross-sectional multinational survey. Support Care Cancer. 2015;23(11):3297\u2013305. https:\/\/doi.org\/10.1007\/s00520-015-2750-5.","journal-title":"Support Care Cancer"},{"issue":"2","key":"2623_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.6004\/jnccn.2012.0018","volume":"10","author":"JM Salsman","year":"2012","unstructured":"Salsman JM, et al. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw. 2012;10(2):149\u201357. https:\/\/doi.org\/10.6004\/jnccn.2012.0018.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2623_CR37","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00520-003-0553-6","volume":"12","author":"F Roila","year":"2004","unstructured":"Roila F. Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Support Care Cancer. 2004;12(6):446\u201353. https:\/\/doi.org\/10.1007\/s00520-003-0553-6.","journal-title":"Support Care Cancer"},{"issue":"2","key":"2623_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1200\/jco.1998.16.2.771","volume":"16","author":"MJ Nolte","year":"1998","unstructured":"Nolte MJ, et al. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1998;16(2):771\u20138. https:\/\/doi.org\/10.1200\/jco.1998.16.2.771.","journal-title":"J Clin Oncol"},{"key":"2623_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/cment.s40219","volume":"9","author":"MK Peltola","year":"2016","unstructured":"Peltola MK, et al. A novel digital patient-reported outcome platform for head and neck oncology patients\u2014a pilot study. Clin Med Insights Ear Nose Throat. 2016;9:1\u20136. https:\/\/doi.org\/10.4137\/cment.s40219.","journal-title":"Clin Med Insights Ear Nose Throat"},{"issue":"4","key":"2623_CR40","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1200\/jco.2004.06.078","volume":"22","author":"G Velikova","year":"2004","unstructured":"Velikova G, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714\u201324. https:\/\/doi.org\/10.1200\/jco.2004.06.078.","journal-title":"J Clin Oncol"},{"key":"2623_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3123","author":"J Chang","year":"2020","unstructured":"Chang J, et al. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3\u2010day aprepitant regimen for prevention of chemotherapy\u2010induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. Cancer Med. 2020. https:\/\/doi.org\/10.1002\/cam4.3123.","journal-title":"Cancer Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02623-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T21:29:13Z","timestamp":1630013353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02623-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2623"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02623-8","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"type":"print","value":"1699-048X"},{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yolanda Escobar \u00c1lvarez has received educational grants, acted as a consultant, attended advisory boards and given lectures for the following organizations: AstraZeneca, Bristol-Myers Squibb, Merck Serono, MSD, Angelini, Vifor Pharma, Kiowa Kirin, and Mylan. Javier De Castro Carpelo has received educational grants from Astra-Zeneca, Boehringer Ingelheim, BMS, MSD, Novartis and Roche, as well as scientific consulting honoraria from Astra-Zeneca, Boehringer Ingelheim, BMS, MSD, Novartis, Pfizer, Roche and Takeda. Danielle Bell, Anthony Drago and Alessandra Franceschetti were full-time employees of Ipsos Healthcare at the time the study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animal performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}